GBC Blog

Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

– Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology – Enabling short-term commercialization of NGS-based molecular microbiology Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 10, 2018; published at 01:00 am EST — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions,…

Read More

Dr. Robert W. Day – Fed Hutchinson Director and Epigenomics CMO

Originally published January 7, 2018 at 5:43 pm Dr. Robert Day, former director of the Fred Hutchinson Cancer Center who brought the campus to South Lake Union, has died at home. Dr. Robert Day, who led the Fred Hutchinson Cancer Center for 16 years and spent much of his retirement working on public-health issues, died…

Read More

Key Tips for Diagnostics in 2018 and Beyond: Development Success in the Evolving US and EU Landscape

TORONTO, ON–(Marketwired – November 29, 2017) – In an upcoming webinar hosted by Xtalks on Thursday, December 14, 2017, leading diagnostics specialty CRO Health Decisions will introduce guest speakers Gail Radcliffe, Ph.D., President of Radcliffe Consulting Inc. and a member of the Health Decisions Scientific Advisory Board, and Jessica Kappes, MBA, MT, CCRA, Health Decisions Project…

Read More

Epigenomics AG Announces Recent Payment Decision by CMS

21. NOVEMBER 2017.   Berlin (Germany) and Germantown, MD (U.S.A.), November 21, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced the Centers of Medicare & Medicaid Services(CMS) has changed their pricing determination for Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer (CRC) screening. In its recently published final payment…

Read More

Epigenomics Initiates €5.5M Private Placement

Epigenomics Initiates €5.5M Private Placement Sep 21, 2017, NEW YORK (GenomeWeb) – Epigenomics said today that it plans to raise approximately €5.5 million ($6.5 million) in a private share placement. The Berlin-based molecular diagnostic firm said that it will increase its share capital in the amount of €1.28 by issuing approximately 1.28 million new registered shares…

Read More

BioreclamationIVT Acquires Biospecimen and Research Services Provider Asterand Bioscience

BioreclamationIVT has acquired Asterand Bioscience™, a global provider of human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advances drug research by accelerating target identification and biomarker validation, and improving drug candidate selection to increase the likelihood of clinical success. “We are delighted that Asterand Bioscience’s talented staff is joining…

Read More

Asterand Bioscience Expands Immuno-oncology Services Capabilities with Vectra Polaris Imaging System

DETROIT & ROYSTON, U.K., July 11, 2017 /EINPresswire.com/ — Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today the introduction of the PerkinElmer Vectra® Polaris™ Automated Quantitative Pathology Imaging System to extend their services capabilities to support scientists in gaining a deeper understanding…

Read More

Recent Data on Curetis Unyvero ITI Application Demonstrate Clinical and Health Economic Benefits

Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits – Several ECCMID 2017 presentations highlight advantages of rapid time to result with Unyvero ITI in Prosthetic Joint Infections Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 27, 2017 – Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer…

Read More

Epigenomics Agrees to Takeover Bid

Epigenomics Agrees to Takeover Bid Apr 26, 2017  NEW YORK (GenomeWeb) – German molecular diagnostics firm Epigenomics announced today that it has agreed to a public takeover offer from Blitz F16-83, a subsidiary of Chinese private equity firm Cathay Fortune International. Under the terms of the deal, Epigenomics shareholders will be offered €7.52 ($8.19) in…

Read More

Curetis Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking

Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking – Product to launch in EMEA at ECCMID Conference April 22-25, 2017 – IAI Panel covers up to 130 diagnostic targets Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 20, 2017 – Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular…

Read More